drugset / Trial / NCT00150059
Efficacy and Safety of Pimecrolimus Cream 1% in Patients ≥ 3 Months of Age With Mild or Moderate Atopic Dermatitis
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To evaluate the efficacy and safety of pimecrolimus cream 1% in its registered indication (treatment of patients \> 3 months of age with mild to moderate atopic dermatitis) This study is not enrolling patients in the United States.
Timeline
- Start
- 2004-12
- Primary completion
- —
- Completion
- 2005-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pimecrolimus | Small molecule | 1 % | — |